Advanced search
Publication Cover
Hematology Volume 25, 2020 - Issue 1
Submit an article Journal homepage
8,875
Views
18
CrossRef citations to date
0
Altmetric
Research Article

The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis

Yuancheng Guoa The First Clinical Medical College, Lanzhou University, Lanzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-9574-2685
ORCID Icon,
Bei Liua The First Clinical Medical College, Lanzhou University, Lanzhou, People’s Republic of ChinaCorrespondence[email protected]
,
Lijuan Denga The First Clinical Medical College, Lanzhou University, Lanzhou, People’s Republic of China
,
Yanhong Qiaob Department of Haematology, Xi'an Central Hospital, Xi’an, Shaanxi, China
&
Jinli Jiana The First Clinical Medical College, Lanzhou University, Lanzhou, People’s Republic of China
Pages 414-423 | Published online: 15 Nov 2020

References

  • Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep. 2016;6:1–7.
  • Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 2006;106(5):1090–1098.
  • Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discovery. 2008;7(12):989–1000.
  • DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
  • Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014;28(8):1657–1665.
  • Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419–425.
  • Higgins JPT, Thompson SG, Deeks JJ. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557.
  • Aldoss I, Yang D, Pillai R, et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Am J Hematol. 2019;94(10):E253–e255.
  • Asghari H, Lee D, Deutsch YE, et al. Outcomes of patients with Relapsed or refractory acute myeloid leukemia Receiving hypomethylating agent and venetoclax. Blood. 2019;134(Suppl 1):1357–1357.
  • Ball BJ, Famulare C, Stein EM, et al. Combined venetoclax and hypomethylating agent (HMA) therapy Induces high response rates in patients with myelodysplastic syndrome including patients Previously Failing HMA. Blood. 2019;134(Suppl 1):4241–4241.
  • Lou Y, Shao L, Mao L, et al. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: A multicenter retrospective study. Leuk Res. 2020;91:106317.
  • Maiti A, DiNardo CD, Rausch CR, et al. Ten-Day decitabine with venetoclax (DEC10-VEN) in acute myeloid leukemia: Updated results of a phase II trial. Blood. 2019;134(Suppl 1):2637–2637.
  • Mittal V, Lo M, Damon LE, et al. Efficacy of venetoclax combination therapy with hypomethylating agents in patients with Relapsed acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Blood. 2019;134(Suppl 1):5089–5089.
  • Rausch CR, DiNardo CD, Maiti A, et al. Venetoclax Dosing in combination with Antifungal agents: Real World Experience in patients with acute myeloid leukemia. Blood. 2019;134(Suppl 1):2640–2640.
  • Wei AH, Garcia JS, Borate U, et al. A phase 1b study evaluating the safety and efficacy of venetoclax in combination with azacitidine in treatment-Naïve patients with higher-risk myelodysplastic syndrome. Blood. 2019;134(Suppl 1):568–568.
  • Winters A, Gutman JA, Purev E, et al. Venetoclax and azacitidine for older Newly diagnosed patients with acute myeloid leukemia: A Single-Institution Pilot study using Measurable Residual disease to Guide therapy. Blood. 2019;134(Suppl 1):2638–2638.
  • Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Advances. 2019;3(20):2911–2919.
  • Zeidan AM, Pollyea DA, Garcia JS, et al. A phase 1b study evaluating the safety and efficacy of venetoclax As monotherapy or in combination with azacitidine for the treatment of Relapsed/refractory myelodysplastic syndrome. Blood. 2019;134(Suppl 1):565–565.
  • Dinardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in Previously Untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–629.
  • Bewersdorf JP, Giri S, Wang R, et al. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2020. doi:10.3324/haematol.2019.242826
  • Ji J, Chen M, Han B. Comparison of Hypomethylator monotherapy with Hypomethylator plus chemotherapy for intermediate/high-risk MDS or AML: A meta-analysis. J Cancer. 2020;11(10):2972–2980.
  • Gao C, Wang J, Li Y, et al. Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis. Medicine (Baltimore. 2018;97(34):e11860–e11860.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.